Anissa Ramirez
Physician Assistant · San Antonio, TXNPI 1003116740
Payments from drug & device makers
Across 231 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$829
- Boehringer Ingelheim$593
- Lilly USA, LLC$582
- Sanofi-aventis U.S. LLC$314
- Johnson & Johnson$250
- Axsome Therapeutics, Inc.$240
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,226100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $829 |
| Boehringer Ingelheim | 30 | $593 |
| Lilly USA, LLC | 30 | $582 |
| Sanofi-aventis U.S. LLC | 17 | $314 |
| Johnson & Johnson | 19 | $250 |
| Axsome Therapeutics, Inc. | 10 | $240 |
| Bayer | 11 | $229 |
| Sumitomo Pharma America, Inc. | 9 | $135 |
| Merck | 7 | $123 |
| Dynavax Technologies Corporation | 9 | $121 |
| GSK | 7 | $115 |
| AstraZeneca(2 entities) | 5 | $96 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $80 |
| Abbott | 3 | $71 |
| Madrigal Pharmaceuticals | 3 | $70 |
| Pfizer | 4 | $70 |
| Amgen | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 4 | $50 |
| AbbVie | 2 | $40 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Corcept Therapeutics | 1 | $18 |
| Novartis | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
How this compares
$4,242 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 135 | $219,395 |
| TrulicityDulaglutide | 79 | $144,422 |
| OzempicSemaglutide | 70 | $95,286 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $50,438 |
| TrintellixVortioxetine Hydrobromide | 39 | $48,102 |
| JanuviaSitagliptin Phosphate | 32 | $39,048 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $38,973 |
| GemtesaVibegron | 36 | $38,857 |
| FarxigaDapagliflozin Propanediol | 27 | $37,921 |
| XareltoRivaroxaban | 21 | $36,677 |
| MounjaroTirzepatide | 25 | $35,935 |
| EliquisApixaban | 40 | $30,261 |
| MyrbetriqMirabegron | 36 | $29,861 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $28,365 |
| LinzessLinaclotide | 22 | $20,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $593 | $235,625158 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $582 | $180,357104 claims |
| Novo NordiskOzempic | $829 | $95,28670 claims |
| MerckJanuvia, Janumet | $123 | $67,41349 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $314 | $50,43860 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $16 | $48,10239 claims |
| GSKTrelegy Ellipta | $115 | $38,97341 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $135 | $38,85736 claims |
| AstraZenecaFarxiga | $96 | $37,92127 claims |
| Johnson & JohnsonXarelto | $250 | $36,67721 claims |
| PfizerEliquis | $70 | $30,26140 claims |
| AbbVieLinzess | $40 | $20,86422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in San Antonio
- Anthony DerenciusSan Antonio$507K
- Andrew PrattSan Antonio$87K
- Sarah MerrittSan Antonio$55K
- Monica ChapmanSan Antonio$38K
- Lisa GarrisonSan Antonio$35K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Brooke HodnickSouthlake$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.